CT-721, a Potent Bcr-Abl Inhibitor, Exhibits Excellent In Vitro and In Vivo Efficacy in the Treatment of Chronic Myeloid Leukemia

Kinase inhibitors that target Bcr-Abl are highly effective in the treatment of chronic myeloid leukemia (CML). However, these inhibitors are often invalidated due to the drug resistance. Therefore, the discovery and development of novel Bcr-Abl inhibitors is required to overwhelm the drug resistance...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Cancer
Main Authors: Sun, Yinghui, Zhao, Na, Wang, Huan, Wu, Qiong, Han, Yunqi, Liu, Qichao, Wu, Mangang, Liu, Yuliang, Kong, Fansheng, Wang, He, Sun, Ying, Sun, Deguang, Jing, Lutao, Tang, Guojing, Hu, Yuandong, Xiao, Dengming, Luo, Hong, Han, Yongxin, Peng, Yong
Formato: Artigo
Idioma:Inglês
Publicado em: Ivyspring International Publisher 2017
Assuntos:
Research Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5604209/
https://ncbi.nlm.nih.gov/pubmed/28928866
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7150/jca.18731
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados